NCT05680818: An ongoing trial by Calcilytix Therapeutics, Inc., a BridgeBio company
This trial is ongoing. It must report results 3 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05680818 |
|---|---|
| Title | CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 6, 2023 |
| Completion date | Aug. 22, 2025 |
| Required reporting date | Aug. 22, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 27, 2026 |
| Days late | None |